218 related articles for article (PubMed ID: 23287530)
21. Olean-28,13b-olide 2 plays a role in cisplatin-mediated apoptosis and reverses cisplatin resistance in human lung cancer through multiple signaling pathways.
Zhu B; Ren C; Du K; Zhu H; Ai Y; Kang F; Luo Y; Liu W; Wang L; Xu Y; Jiang X; Zhang Y
Biochem Pharmacol; 2019 Dec; 170():113642. PubMed ID: 31541631
[TBL] [Abstract][Full Text] [Related]
22. NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells.
Jiang P; Wu X; Wang X; Huang W; Feng Q
Oncotarget; 2016 Jul; 7(28):43337-43351. PubMed ID: 27270317
[TBL] [Abstract][Full Text] [Related]
23. Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin.
Huang CP; Fofana M; Chan J; Chang CJ; Howell SB
Metallomics; 2014 Mar; 6(3):654-61. PubMed ID: 24522273
[TBL] [Abstract][Full Text] [Related]
24. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
25. Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7B.
Dmitriev OY
Biochem Cell Biol; 2011 Apr; 89(2):138-47. PubMed ID: 21455266
[TBL] [Abstract][Full Text] [Related]
26. Cross-resistance to cisplatin in cells with acquired resistance to copper.
Safaei R; Katano K; Samimi G; Naerdemann W; Stevenson JL; Rochdi M; Howell SB
Cancer Chemother Pharmacol; 2004 Mar; 53(3):239-46. PubMed ID: 14648017
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of LIPC in non-small cell lung carcinoma.
Galluzzi L; Goubar A; Olaussen KA; Vitale I; Senovilla L; Michels J; Robin A; Dorvault N; Besse B; Validire P; Fouret P; Behrens C; Wistuba II; Soria JC; Kroemer G
Cell Cycle; 2013 Feb; 12(4):647-54. PubMed ID: 23343765
[TBL] [Abstract][Full Text] [Related]
28. Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells.
Beretta GL; Gatti L; Tinelli S; Corna E; Colangelo D; Zunino F; Perego P
Biochem Pharmacol; 2004 Jul; 68(2):283-91. PubMed ID: 15194000
[TBL] [Abstract][Full Text] [Related]
29. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
Samimi G; Safaei R; Katano K; Holzer AK; Rochdi M; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2004 Jul; 10(14):4661-9. PubMed ID: 15269138
[TBL] [Abstract][Full Text] [Related]
30. Curcumin enhances cisplatin sensitivity of human NSCLC cell lines through influencing Cu-Sp1-CTR1 regulatory loop.
Zhang W; Shi H; Chen C; Ren K; Xu Y; Liu X; He L
Phytomedicine; 2018 Sep; 48():51-61. PubMed ID: 30195880
[TBL] [Abstract][Full Text] [Related]
31. Elevated pressure, a novel cancer therapeutic tool for sensitizing cisplatin-mediated apoptosis in A549.
Oh S; Kim Y; Kim J; Kwon D; Lee E
Biochem Biophys Res Commun; 2010 Aug; 399(1):91-7. PubMed ID: 20643104
[TBL] [Abstract][Full Text] [Related]
32. Sec61β controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A.
Abada PB; Larson CA; Manorek G; Adams P; Howell SB
Mol Pharmacol; 2012 Sep; 82(3):510-20. PubMed ID: 22710939
[TBL] [Abstract][Full Text] [Related]
33. The role of the methionines and histidines in the transmembrane domain of mammalian copper transporter 1 in the cellular accumulation of cisplatin.
Larson CA; Adams PL; Blair BG; Safaei R; Howell SB
Mol Pharmacol; 2010 Sep; 78(3):333-9. PubMed ID: 20519567
[TBL] [Abstract][Full Text] [Related]
34. A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells.
Ivy KD; Kaplan JH
Mol Pharmacol; 2013 Jun; 83(6):1237-46. PubMed ID: 23543413
[TBL] [Abstract][Full Text] [Related]
35. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.
Song IS; Savaraj N; Siddik ZH; Liu P; Wei Y; Wu CJ; Kuo MT
Mol Cancer Ther; 2004 Dec; 3(12):1543-9. PubMed ID: 15634647
[TBL] [Abstract][Full Text] [Related]
36. Overcoming platinum drug resistance with copper-lowering agents.
Chen HH; Kuo MT
Anticancer Res; 2013 Oct; 33(10):4157-61. PubMed ID: 24122978
[TBL] [Abstract][Full Text] [Related]
37. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
38. Copper transport systems are involved in multidrug resistance and drug transport.
Furukawa T; Komatsu M; Ikeda R; Tsujikawa K; Akiyama S
Curr Med Chem; 2008; 15(30):3268-78. PubMed ID: 19075668
[TBL] [Abstract][Full Text] [Related]
39. Dual role of LRRC8A-containing transporters on cisplatin resistance in human ovarian cancer cells.
Sørensen BH; Dam CS; Stürup S; Lambert IH
J Inorg Biochem; 2016 Jul; 160():287-95. PubMed ID: 27112899
[TBL] [Abstract][Full Text] [Related]
40. Collateral sensitivity to cisplatin in KB-8-5-11 drug-resistant cancer cells.
Doherty B; Lawlor D; Gillet JP; Gottesman M; O'Leary JJ; Stordal B
Anticancer Res; 2014 Jan; 34(1):503-7. PubMed ID: 24403508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
